MMED

NEUTRAL

$14.39 Live

Minimed Group, Inc. · NASDAQ

Target $22.45 (+56.0%)

$12.8 52W Range $20.48

MMED Minimed Group, Inc. - Fundamental Analysis

NEUTRAL

Console Chart News

MMED Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Health Information Services

Current Price Live

$14.39

Analyst Target

$22.45

+56.0% Upside

52W High

$20.48

52W Low

$12.8

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 14, 2026

Market cap

$4.04B

P/E

N/A

ROE

N/A

Profit margin

-7.3%

Debt/Equity

0.02

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

75%

MMED presents a dichotomy between strong fundamental health and poor market performance. The Piotroski F-Score of 5/9 indicates a stable financial condition, supported by an exceptionally low Debt/Equity ratio of 0.02 and a healthy Current Ratio of 1.77. However, the stock is in a severe technical downtrend with a 0/100 trend score and consistent -22.2% returns over multiple time horizons. While analysts maintain a 'strong_buy' with a target of $22.45, the company's negative profit margin (-7.31%) and bearish insider sentiment (40/100) suggest significant headwinds before a recovery is realized.

Key Strengths

Extremely low leverage (Debt/Equity: 0.02)

Strong Gross Margin (56.79%) indicating efficient core production

Stable Piotroski F-Score (5/9)

Strong analyst consensus (Strong Buy from 11 analysts)

Healthy liquidity with a Current Ratio of 1.77

Key Risks

Persistent negative net profit margins (-7.31%)

Severe long-term price depreciation (-22.2% over 1Y, 3Y, and 5Y)

Bearish technical trend (0/100 score)

Weak insider sentiment (40/100)

Lack of dividend income or payout history

AI Fair Value Estimate

Based on comprehensive analysis

$18.42

+28.0% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Moderate

Value

Future

Past

Health

Dividend

AI Verdict

Speculative Recovery

Key drivers: Pristine balance sheet, Strong analyst price targets, Chronic price underperformance, Transition to profitability

Confidence

70%

Value

60/100

Valuation is based on forward expectations rather than current earnings.

Positives

Low Price/Sales ratio (1.40)
Reasonable Forward P/E (21.44)

Watchpoints

Lack of current earnings for P/E valuation
No Graham Number available

Future

65/100

Future outlook is heavily reliant on analyst projections and revenue scaling.

Positives

13.10% YoY Revenue Growth
High analyst target price ($22.45)

Watchpoints

Growth is moderate compared to sector averages

Past

20/100

Historical price action is overwhelmingly bearish.

Positives

Recent 1-week bounce (+8.8%)

Watchpoints

Consistent -22.2% return across 1Y, 3Y, and 5Y periods

Health

85/100

Balance sheet is the strongest component of the company's profile.

Positives

Near-zero debt
Piotroski F-Score of 5/9
Strong current and quick ratios

Watchpoints

Negative net profit margin

Dividend

0/100

Company does not return capital to shareholders.

Positives

No standout positives identified.

Watchpoints

No dividend yield
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$14.39

Analyst Target

$22.45

Upside/Downside

+56.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MMED and closest competitors.

Updated 2026-04-13

Company	5Y	3Y	1Y	6M	1M	1W
MMED Minimed Group, Inc. Primary	-22.2%	-22.2%	-22.2%	-22.2%	-8.7%	+8.8%
LGND Ligand Pharmaceuticals Incorporated Peer	+126.7%	+173.3%	+102.3%	+15.3%	-7.4%	+2.7%
ALHC Alignment Healthcare, Inc. Peer	+11.0%	+93.4%	+42.7%	+17.5%	-12.9%	-6.7%
INDV Indivior Pharmaceuticals, Inc. Peer	+218.1%	+75.0%	+241.6%	+28.4%	-7.0%	+0.2%
IRTC iRhythm Holdings, Inc. Peer	+43.4%	-13.2%	+16.6%	-34.6%	-3.7%	-1.3%

MME

Minimed Group, Inc.

Primary

-22.2%

-8.7%

+8.8%

LGN

Ligand Pharmaceuticals Incorporated

Peer

+126.7%

+173.3%

+102.3%

+15.3%

-7.4%

+2.7%

ALH

Alignment Healthcare, Inc.

Peer

+11.0%

+93.4%

+42.7%

+17.5%

-12.9%

-6.7%

IND

Indivior Pharmaceuticals, Inc.

Peer

+218.1%

+75.0%

+241.6%

+28.4%

-7.0%

+0.2%

IRT

iRhythm Holdings, Inc.

Peer

+43.4%

-13.2%

+16.6%

-34.6%

-3.7%

-1.3%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

21.44

N/A

1.4

N/A

$4.04B

Profitability

Profit margins and return metrics

Profit Margin -7.31%

Operating Margin 1.36%

Gross Margin 56.79%

ROE N/A

ROA N/A

Growth

Revenue and earnings growth rates

Revenue Growth +13.1%

Earnings Growth N/A

Q/Q Revenue Growth N/A

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.02

Low debt

Current Ratio

1.77

Good

Quick Ratio

1.06

Good

Cash/Share

$N/A

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Total Assets

$4.2B

Liabilities

$0.5B

Equity

$3.7B

Debt/Equity

0.13x

Healthcare Sector Comparison

Comparing MMED against 319 companies in the Healthcare sector (20 bullish, 107 neutral, 192 bearish)

Profit Margin

-7.31%

This Stock

-11.76%

Sector Avg

-37.8% (Weaker)

Debt to Equity

0.02

This Stock

3.51

Sector Avg

-99.5% (Less Debt)

Revenue Growth

13.1%

This Stock

90.15%

Sector Avg

-85.5% (Slower)

Current Ratio

1.77

This Stock

3.67

Sector Avg

-51.7% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
MMED Minimed Group, Inc.	NEUTRAL	$4.04B	-	-%	-7.3%	$14.39
LGND Ligand Pharmaceuticals Incorporated	NEUTRAL	$4.09B	33.43	13.5%	46.4%	$204.92	Compare
ALHC Alignment Healthcare, Inc.	BEARISH	$3.85B	-	-0.7%	-0.0%	$19.22	Compare
INDV Indivior Pharmaceuticals, Inc.	NEUTRAL	$3.82B	18.62	-%	16.9%	$30.54	Compare
IRTC iRhythm Holdings, Inc.	NEUTRAL	$3.72B	-	-36.6%	-6.0%	$115.24	Compare

MMED Minimed Group, Inc.

NEUTRAL

Mkt Cap

$4.0B

P/E

ROE

Price

$14.39

Compare with MMED

Compare with MMED

Compare with MMED

IRTC iRhythm Holdings, Inc.

Compare with MMED

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

STRONG_BUY

11 analysts

Barclays

2026-04-01

init

Overweight

William Blair

2026-03-31

init

Outperform

Citigroup

2026-03-31

init

Buy

Piper Sandler

2026-03-31

init

Neutral

Mizuho

2026-03-31

init

Outperform

Wells Fargo

2026-03-31

init

Overweight

Morgan Stanley

2026-03-31

init

Overweight

Evercore ISI Group

2026-03-31

init

Outperform

B of A Securities

2026-03-31

init

Buy

BTIG

2026-03-31

init

Buy

Past News Coverage

Recent headlines mentioning MMED from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

MMED

MMED Minimed Group, Inc. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!